Asahi Kasei Bioprocess to Showcase Award-winning MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing at ACHEMA 2022

Düsseldorf, 27 July 2022 – Asahi Kasei Bioprocess, subsidiary of diversified Japanese technology company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August. Using built-in automation software, MOTIV keeps pharmaceutical production moving efficiently and precisely, so that medicine can be produced in larger quantities, be made more available globally and can get to patients sooner and safer.

Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF™), Asahi Kasei Bioprocess has been constantly pushing the boundaries in the field of buffer formulation systems.

MOTIV™ Puffermanagement-Technologie, Buffer Management Technology

Sustainable pharmaceutical production

Buffers are used for the vast majority of processes in pharmaceutical development, which has traditionally required storage in extremely large tank farms to be utilized as necessary. MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision. It is also able to blend buffers to exact specifications as needed during a downstream development process and can handle a wide variety of buffer formulations. In addition, it is automated by the integrated OCELOT™ System Control software, a technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for far-reaching data collection and analysis. OCELOT™ makes the whole process repeatable and also helps to reduce waste created in the development process, so it is a more sustainable means of pharmaceutical manufacturing.

“We have been working to ‘standardize’ system designs as much as we can, to make them more readily available with shorter lead times; but are also very capable at building custom systems to meet the specific needs of customers,” says Chris Rombach, Vice President of Sales and Marketing at Asahi Kasei Bioprocess America.

“One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from. Buffer is the lifeblood of pharma manufacturing and with the R&D opportunities of being a part of the Asahi Kasei Group we have been able to develop MOTIV to be the most reliable and efficient IBF technology in the market today. Not to mention, Operation Warp Speed helped push capacity to expand globally and billions of dollars are being invested by manufacturers to ramp up production as quickly as possible. This drives a new sense of value for systems like our MOTIV family that can streamline processes.”

Asahi Kasei Bioprocess will display its solutions from 22-26 August 2022 at ACHEMA, the leading international event for the process industry, in Frankfurt, Germany (Hall 4.1, Stand G27).

MOTIV™ Puffermanagement-Technologie, Buffer Management Technology

About Asahi Kasei Bioprocess
Asahi Kasei Bioprocess is the global market leader in virus filtration, with its Planova™ virus removal filters having an unrivaled 30-year history of trusted use in the production of biotherapeutics. We aim to provide “Assurance Beyond Expectation” to pharmaceutical companies in the form of innovative yet exceptionally reliable bioprocess consumables, equipment, and support services, to help them safely and efficiently produce medicines that patients can trust. For more information, please visit https://www.ak-bio.com.

About the Asahi Kasei Corporation
Asahi Kasei Corporation is a globally active diversified technology company with operations in the Material, Homes, and Health Care business sectors. The Material sector encompasses fibers & textiles, petrochemicals, performance polymers, performance materials, consumables, battery separators, and electronic devices. The Homes sector provides housing and construction materials to the Japanese market. The Health Care sector includes pharmaceuticals, medical devices, and acute critical care devices and systems. With more than 46,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries and achieved sales of 18.9 billion euros (2,461 billion yen) in the fiscal year 2021 (April 1, 2021 – March 31, 2022).

Asahi Kasei is “Creating for Tomorrow” with all operations sharing a common mission of contributing to life and living for people around the world. For more information, visit

www.asahi-kasei.eu, www.asahi-kasei.com and https://www.asahi-kasei.com/sustainability/.

Company Contact Europe:
Asahi Kasei Europe GmbH
Sebastian Schmidt Fringsstrasse 17, 40221 Düsseldorf
Tel: +49 (0) 211-3399-2058
Mail: sebastian.schmidt@asahi-kasei.eu

SunForce

Technical Particle Foams

Packaging Products

Packaging Products

Synthetic Rubber

Synthetic Rubber

Hydrogen

Hydrogen

Coating Material

Coating Material

Membranes and Systems

Membranes and Systems

Asahi Kasei Ventures

Asahi Kasei Ventures

Pharmaceutical Materials

Pharmaceutical Materials

Industrie Automotive

Automotive Industry

Health Care

Health Care

Food and Beverages

Food and Beverages

Clean Energy

Clean Energy

Automation Systems

Automation Systems

IoT Internet of Things
IoT Internet of Things